Business, energy, technology, markets and global industry news from Business News Today

Flagship Pioneering

PharmaDeviceNews Flagship Pioneering
Sail Biomedicines’ in vivo CAR-T collaboration with Johnson & Johnson highlights growing investment in RNA-based immune-cell therapies for autoimmune diseases. Representative image.
Pharma & Biotech

Why Johnson & Johnson is staking $785m on Sail’s in vivo CAR-T platform before human trials

Johnson & Johnson backs Sail Biomedicines’ in vivo CAR-T platform with $785 million in initial payments and a $2.58 billion buyout option.

Read More
Representative image illustrating advanced immunotherapy research, as Pfizer and Repertoire Immune Medicines explore T cell receptor bispecific approaches for metastatic prostate cancer treatment.
Pharma & Biotech

Can TCR bispecifics unlock prostate cancer immunotherapy? Why Pfizer is backing Flagship and Repertoire

Flagship Pioneering has launched a new research program with Pfizer through its portfolio company Repertoire Immune Medicines, focused on the development of T cell receptor (TCR) bispecifics for metastatic prostate cancer. This marks the eighth initiative under the broader Flagship–Pfizer strategic alliance. The program will harness Repertoire’s DECODE platform to map immune synapse interactions and

Read More